Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Günter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack, Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Theresa Mokry, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Dimo Dietrich, Jonas Saal, Jörg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua Meeks, Francisco E Vera Badillo, J Alberto Nakauma-González, Joost Boormans, Kerstin Junker, Arndt Hartmann, Viktor Grünwald, Michael Hölzel, Markus Eckstein
PURPOSE: The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) in urothelial cancer. Here, we aimed to evaluate NECTIN4 amplifications as a genomic biomarker to predict EV response in patients with mUC. MATERIALS AND METHODS: We established a NECTIN4 -specific fluorescence in situ hybridization (FISH) assay to assess the predictive value of NECTIN4 CNVs in a multicenter EV-treated mUC patient cohort (mUC-EV, n = 108)...
April 24, 2024: Journal of Clinical Oncology
#2
Noura Abbas, Laudy Chehade, Ali Shamseddine
Bladder cancer (BC) poses a significant health challenge, particularly in metastatic cases, where the prognosis is unfavorable and therapeutic options are limited. Poly ADP-ribose polymerase (PARP) inhibitors have gained approval for use in various cancer types, but their application in BC remains controversial, despite the notable prevalence of DNA damage response alterations in advanced or metastatic urothelial carcinomas. In this report, we describe a 66-year-old heavy-smoking female diagnosed with muscle-invasive BC...
2024: Therapeutic Advances in Medical Oncology
#3
REVIEW
Sophia Bhalla, Rachel Passarelli, Antara Biswas, Subhajyoti De, Saum Ghodoussipour
Bladder cancer (BC) is one of the most common malignancies in the United States, with over 80,000 new cases and 16,000 deaths each year. Urothelial carcinoma (UC) is the most common histology and accounts for 90% of cases. BC management is complicated by recurrence rates of over 50% in both muscle-invasive and non-muscle-invasive bladder cancer. As such, the American Urological Association (AUA) recommends that patients undergo close surveillance during and after treatment. This surveillance is in the form of cystoscopy or imaging tests, which can be invasive and costly tests...
April 2, 2024: Journal of Clinical Medicine
#4
JOURNAL ARTICLE
Renate Pichler, Johannes Stäblein, Andrea Mari, Luca Afferi, David D'Andrea, Gautier Marcq, Francesco Del Giudice, Francesco Soria, Jorge Caño-Velasco, José Daniel Subiela, Andrea Gallioli, Karl H Tully, Keiichiro Mori, Achim Herms, Benjamin Pradere, Marco Moschini, Laura S Mertens, Martin Thurnher
In non-muscle invasive bladder cancer, Bacillus Calmette-Guérin (BCG) responders benefit from strong Th1-type inflammatory and T cell responses mediating tumor rejection. However, the corresponding lack of anti-inflammatory Th2-type immunity impairs tissue repair in the bladder wall and facilitates the development of cystitis, causing urinary pain, urgency, incontinence, and frequency. Mechanistically, the leakage of the glycosaminoglycan (GAG) layer enables an influx of potassium ions, bacteria, and urine solutes towards the underlying bladder tissue, promoting chronic inflammation...
March 31, 2024: Journal of Clinical Medicine
#5
JOURNAL ARTICLE
Seong Hyeon Yu, Sung Sun Kim, Shinseung Kim, Hyungki Lee, Taek Won Kang
Background: Mutations of fibroblast growth factor receptor 3 ( FGFR3 ) are associated with urothelial carcinoma (UC) oncogenesis and are considered an important therapeutic target. Therefore, we evaluated the FGFR3 mutation rate and its clinical significance in urothelial carcinoma (UC) using next-generation sequencing. Methods: A total of 123 patients with UC who were treated at Chonnam National University Hospital (Gwang-ju, Korea) from January 2018 to December 2020 were enrolled. We performed NGS using the Oncomine panel with tumor specimens and blood samples corresponding to each specimen...
February 25, 2024: Journal of Clinical Medicine
#6
JOURNAL ARTICLE
Nadeem Bin Nusrat, Assad Ur Rehman, Nauman Zafar, Shujah Muhammad, Sarmad Imtiaz Bajwa, Saira Imtiaz
OBJECTIVE: To evaluate long-term outcomes in patients homogenously treated with radical cystectomy and ileal conduit for muscle invasive bladder cancer. METHODS: The retrospective study was conducted at the Urology Department of Pakistan Kidney and Liver Institute and Research Centre, Lahore, Pakistan, and comprised data from December 25, 2017, to January 16, 2023, related to patients who underwent radical cystectomy with ileal conduit with or without neo-adjuvant and adjuvant radiation, chemotherapy, or immunotherapy for papillary urothelial carcinom of the bladder...
March 2024: JPMA. the Journal of the Pakistan Medical Association
#7
JOURNAL ARTICLE
Ursula M Vogl, Irene Testi, Maria De Santis
Cisplatin remains a valid option in muscle-invasive or metastatic urothelial carcinoma, and is even more efficient when nivolumab is added. The well-known side-effect profile and the limited number of treatment cycles represent great advantages over modern drug combinations such as enfortumab-vedotin plus pembrolizumab.
April 5, 2024: European Urology Focus
#8
JOURNAL ARTICLE
Chanchan Zhang, Xiaohong Xu, Tao Wang, Yan Lu, Zhiheng Lu, Tuantuan Wang, Zhiwen Pan
Traditional clinical modalities for diagnosing bladder urothelial carcinoma (BUC) remain limited due to their invasive nature, significant costs, discomfort associated with cystoscopy, and low sensitivity to urine cytology. Therefore, there is an urgent need to identify highly sensitive, specific, and noninvasive biomarkers for the early detection of this neoplasm. Hypermethylated TWIST1/Vimentin promoter may be a noninvasive biomarker using urine sample. We assessed the TWIST1/Vimentin promoter methylation status in urine samples using the Methylated Human TWIST1 and Vimentin Gene Detection Kit (Jiangsu MicroDiag Biomedicine Co...
April 4, 2024: Scientific Reports
#9
REVIEW
M López Valcárcel, M Barrado Los Arcos, M Ferri Molina, I Cienfuegos Belmonte, V Duque Santana, P Gajate Borau, J Fernández Ibiza, M Álvarez Maestro, P Sargos, F López Campos, F Couñago
OBJECTIVE: The aim of this review is to summarize the current evidence and future perspectives of bladder-sparing treatment for MIBC. METHODS: A non-systematic literature search in Medline/Pubmed was performed in October 2023 with the following keywords "bladder cancer", "bladder-sparing", "trimodal therapy", "chemoradiation", "biomarkers", "immunotherapy", "neoadjuvant chemotherapy", radiotherapy". RESULTS: Urology guidelines recommend radical cystectomy as the standard curative treatment for muscle-invasive urothelial bladder cancer, reserving radiotherapy for patients who are unfit or who want to maintain their bladder...
April 2, 2024: Actas urologicas españolas
#10
REVIEW
Scot A Niglio, Juhi M Purswani, Peter B Schiff, Jonathan W Lischalk, William C Huang, Katie S Murray, Andrea B Apolo
PURPOSE OF REVIEW: The most common definitive treatment for muscle-invasive bladder cancer (MIBC) is radical cystectomy. However, removing the bladder and surrounding organs poses risks of morbidity that can reduce quality of life, and raises the risk of death. Treatment strategies that preserve the organs can manage the local tumor and mitigate the risk of distant metastasis. Recent data have demonstrated promising outcomes in several bladder-preservation strategies. RECENT FINDINGS: Bladder preservation with trimodality therapy (TMT), combining maximal transurethral resection of the bladder tumor, chemotherapy, and radiotherapy (RT), was often reserved for nonsurgical candidates for radical cystectomy...
May 1, 2024: Current Opinion in Oncology
#11
JOURNAL ARTICLE
Sarmad Al-Marsoummi, Aaron A Mehus, Scott H Garrett, Donald A Sens, Seema Somji
Bladder cancer (BC) is the eighth most common cause of cancer death in the United States of America. BC is classified into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Genetically, MIBCs are categorized into the more aggressive basal subtype or less aggressive luminal subtype. All-trans retinoic acid (tretinoin), the ligand for the RAR-RXR retinoic acid receptor, is clinically used as a differentiation therapy in hematological malignancies. This study aims to determine the effects of retinoic acid on arsenite-transformed malignant urothelial cells (UROtsa As), serving as a model for basal muscle-invasive bladder cancer...
March 17, 2024: Cancers
#12
JOURNAL ARTICLE
Paulo Rodolfo Moraes Dos Santos, Paulo Ricardo da Silva Gomes, Poliana Romão, Feres Camargo Maluf, Vanessa Ribeiro Guimarães, Patrícia Candido, Guilherme Lopes Gonçalves, Juliana Alves de Camargo, Gabriel Arantes Dos Santos, Iran Silva, Katia Ramos Moreira Leite, William Nahas, Sabrina T Reis, Ruan Pimenta, Nayara Izabel Viana
Bladder carcinoma (BC) is the tenth most frequent malignancy worldwide, with high morbidity and mortality rates. Despite recent treatment advances, high-grade BC and muscle-invasive BC present with significant progression and recurrence rates, urging the need for alternative treatments. The microRNA-21 (miR-21) has superexpression in many malignancies and is associated with cellular invasion and progression. One of its mechanisms of action is the regulation of RECK, a tumor suppressor gene responsible for inhibiting metalloproteinases, including MMP9...
March 24, 2024: Biochemical Genetics
#13
JOURNAL ARTICLE
Taku Murakami, Keita Minami, Toru Harabayashi, Satoru Maruyama, Norikata Takada, Akira Kashiwagi, Haruka Miyata, Yasuyuki Sato, Ryuji Matsumoto, Hiroshi Kikuchi, Takashige Abe, Yoichi M Ito, Sachiyo Murai, Nobuo Shinohara, Hiroshi Harada, Takahiro Osawa
We designed this multi-center prospective study with the following objectives: (1) the cross-sectional validation of extracellular vesicles (EV) mRNA markers to detect urothelial bladder cancer (UBC) before transurethral resection of bladder cancer (TURBT), and (2) the longitudinal validation of EV mRNA markers to monitor non-muscle invasive bladder cancer (NMIBC) recurrence after TURBT. EV mRNA markers evaluated in this study were KRT17, GPRC5A, and SLC2A1 in addition to two additional markers from literatures, MDK and CXCR2, and measured by quantitative RT-PCR with normalization by a reference gene (ALDOB)...
March 21, 2024: Scientific Reports
#14
JOURNAL ARTICLE
Shunsuke Ikuma, Jun Akatsuka, Hayato Takeda, Yuki Endo, Tomonari Kiriyama, Tsutomu Hamasaki, Go Kimura, Yukihiro Kondo
BACKGROUND: The Vesical Imaging Reporting and Data System (VI-RADS) is widely used for predicting muscle-invasive bladder cancer (MIBC). This study aimed to determine the clinicopathological significance of the VI-RADS ≧4 (VI≧4) group. METHODS: Patients who underwent transurethral resections of bladder tumors during the study period and preoperative magnetic resonance imaging were considered. The patients were pathologically diagnosed with urothelial carcinoma (UC)...
March 20, 2024: BMC Urology
#15
JOURNAL ARTICLE
Haim Herzberg, Roi Babaoof, Ron Marom, Yotam Veredgorn, Ziv Savin, Karin Lifshitz, Shmulik Noefeld, Rinat Lasmanovitz, Shayel Bercovich, Tomer Lamhoot, Sharon Amir, Avi Beri, David Margel, Jack Baniel, Roy Mano, Ofer Yossepowitch
BACKGROUND AND OBJECTIVE: We compared the oncologic outcomes of patients with non-muscle invasive bladder cancer (NMIBC) who underwent transurethral resection of bladder tumor (TUBRT) using sterile water vs glycine irrigation. The tumoricidal and immunogenic effects of these solutions on urothelial cancer cell lines were investigated. METHODS: The medical records of 530 consecutive patients who underwent TURBT using sterile water or glycine irrigation for NMIBC were reviewed...
March 19, 2024: European Urology Focus
#16
JOURNAL ARTICLE
Clément Klein, Serge Brunelle, Mathias Illy, Valeria De Luca, Laure Doisy, François Lannes, Davidson Sypre, Nicolas Branger, Thomas Maubon, Stanislas Rybikowski, Mathilde Guérin, Gwenaëlle Gravis, Jochen Walz, Geraldine Pignot
PURPOSE: The standard follow-up for non-muscle-invasive bladder cancer is based on cystoscopy. Unfortunately, post-instillation inflammatory changes can make the interpretation of this exam difficult, with lower specificity. This study aimed to evaluate the interest of bladder MRI in the follow-up of patients following intravesical instillation. METHODS: Data from patients who underwent cystoscopy and bladder MRI in a post-intravesical instillation setting between February 2020 and March 2023 were retrospectively collected...
March 20, 2024: World Journal of Urology
#17
JOURNAL ARTICLE
Jessie L Chai, Lauren A Roller, Xiaoyang Liu, Zhou Lan, Matthew Mossanen, Stuart G Silverman, Atul B Shinagare
PURPOSE: To assess VIRADS performance and inter-reader agreement for detecting muscle-invasive bladder cancer (MIBC) following transurethral resection of bladder tumor (TURBT). METHODS: An IRB-approved, HIPAA-compliant, retrospective study from 2016 to 2020 included patients with bladder urothelial carcinoma who underwent MRI after TURBT, and cystectomy within 3 months without post-MRI treatments. Three radiologists blinded to pathology results independently reviewed MR images and assigned a VI-RADS score...
March 19, 2024: Abdominal Radiology
#18
JOURNAL ARTICLE
Dickon Hayne, Katherine Ong, Nicole Swarbrick, Steve P McCombie, Andrew Moe, Cynthia Hawks, Pravin Viswambaram, Ciara Conduit, Elizabeth Liow, Lisa Spalding, Jayne Lim, Thomas Ferguson, Katie Meehan, Ian D Davis, Andrew D Redfern
OBJECTIVES: To assess the safety of sub-urothelial injection of durvalumab and examine the impact on tissue and circulating immune cell populations. PATIENTS AND METHODS: The patients were chemotherapy and immunotherapy naïve (bacille Calmette-Guérin allowed) with non-metastatic muscle-invasive bladder cancer or non-muscle-invasive bladder cancer planned for radical cystectomy (RC). The study was a Phase Ib 3 + 3 dose-escalation design with sub-urothelial injection of durvalumab at three pre-determined doses (25, 75, 150 mg) diluted in 25 mL normal saline, injected at 25 locations (25 × 1 mL injections), at least 2 weeks before RC...
March 12, 2024: BJU International
#19
JOURNAL ARTICLE
Sarah Flury-Sutter, Frederick Heuzeroth, Emilio Arbelaez, Lukas Bubendorf, Heike Püschel, Stefanie Hayoz, Cyrill A Rentsch
INTRODUCTION: Little is known about the efficacy and tolerability of intravesical bacillus Calmette-Guérin (BCG) strain Russia for treatment of non-muscle-invasive bladder cancer (NMIBC) in a middle- European population. METHODS: A prospective collection of outcomes of 101 BCG-naive patients with urothelial bladder carcinoma was carried out between January 2013 and October 2023 at the University Hospital Basel, Basel, Switzerland. Patients underwent BCG (ONCO-BCGSIIL, Serum Institute of India, Pune, India) induction and a maximum of three maintenance cycles within one year...
March 1, 2024: Canadian Urological Association Journal
#20
JOURNAL ARTICLE
Luca Afferi, Martin Spahn, Stefanie Hayoz, Räto T Strebel, Sacha I Rothschild, Helge Seifert, Berna C Özdemir, Bernhard Kiss, Philipp Maletzki, Daniel Engeler, Gregory Wirth, Boris Hadaschik, Ilaria Lucca, Hubert John, Andreas Sauer, Michael Müntener, Lukas Bubendorf, Martina Schneider, Jana Musilova, Ulf Petrausch, Richard Cathomas
OBJECTIVE: To report on the surgical safety and quality of pelvic lymph node dissection (PLND) in patients treated with radical cystectomy (RC) and PLND for muscle-invasive bladder cancer (MIBC) after neoadjuvant chemo-immunotherapy. PATIENTS AND METHODS: The Swiss Group for Clinical Cancer Research (SAKK) 06/17 was an open-label single-arm phase II trial including 61 cisplatin-fit patients with clinical stage (c)T2-T4a cN0-1 operable urothelial MIBC or upper urinary tract cancer...
March 8, 2024: BJU International
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
